Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Sep 15, 2025; 17(9): 109127
Published online Sep 15, 2025. doi: 10.4251/wjgo.v17.i9.109127
Published online Sep 15, 2025. doi: 10.4251/wjgo.v17.i9.109127
Methionyl-tRNA synthetase 1 participates in hepatocellular carcinoma and its regulated gene profile possesses potent prognostic ability
Hai-Yan Bu, Ze-Bing Huang, Yan Huang, Yu-Kun Huang, Li Wu, Jiao Yuan, Song-Man Yu, Pan-Pan Yi, Xing-Wang Hu, Department of Infectious Diseases, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China
Hong Huang, Rong-Jun Wang, School of Medicine, Guilin Medical University, Guilin 541199, Guangxi Zhuang Autonomous Region, China
Jia Li, Ai-Min Wang, Department of Emergency Medicine, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China
Min Lu, Yu-Peng Jiang, Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha 410000, Hunan Province, China
Ya-Yu Chen, Xing-Wang Hu, Hunan Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China
Xing-Wang Hu, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China
Co-corresponding authors: Yu-Peng Jiang and Xing-Wang Hu.
Author contributions: Jiang YP and Hu XW designed and coordinated the study and they contribute equally to this study as co-corresponding authors; Bu HY, Huang H, Li J, Huang ZB, Huang Y, Huang YK and Wang AM performed the experiments, acquired and analyzed data; Wu L, Yuan J, Wang RJ, Lu M, Yu SM, Yi PP and Chen YY interpreted the data; Bu HY, Jiang YP and Hu XW wrote the manuscript; all authors approved the final version of the article.
Supported by National Natural Science Foundation of China, No. 82300694 and No. 81970523, Natural Science Foundation of Hunan Province, No. 2022JJ70165, No. 2021JJ31067, No. 2023JJ40828 and No. 2022JJ40704.
Institutional review board statement: The study was reviewed and approved by the Ethics Committee of Xiangya Hospital (Approval No. 202009881).
Institutional animal care and use committee statement: All procedures involving animals were reviewed and approved by the Experimental Animal Ethics Review Committee of Xiangya Hospital (IACUC protocol No. 202310052).
Conflict-of-interest statement: All authors declare no competing financial or non-financial interests.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Data sharing statement: The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xing-Wang Hu, PhD, Associate Researcher, Department of Infectious Diseases, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Changsha 410008, Hunan Province, China. lebithu@csu.edu.cn
Received: May 12, 2025
Revised: June 6, 2025
Accepted: July 23, 2025
Published online: September 15, 2025
Processing time: 128 Days and 8.6 Hours
Revised: June 6, 2025
Accepted: July 23, 2025
Published online: September 15, 2025
Processing time: 128 Days and 8.6 Hours
Core Tip
Core Tip: Aminoacyl-tRNA synthetases (ARSs) are important regulators implicated in the occurrence and progression of several cancers. However, their specific function in hepatocellular carcinoma (HCC) remains unclear, and effective ARSs-related prognostic risk factors for stratifying patients are lacking. In this study, we identified that Methionyl-tRNA synthetase 1 (MARS1) promotes the proliferation, migration, invasion, and tumor formation of hepatoma cells in vitro and in vivo, highlighting its potential as a therapeutic target for HCC. Moreover, we established MARS1-related prognostic score as an independent prognostic factor for patient survival and a predictor of tumor treatment response, contributing valuable insights into the development of personalized treatment strategies.